NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ELAB

PMGC Holdings Inc

Jun 30 • 04:00PM ET

2.16

Dollar change +0.02
Percentage change 0.93	%

Healthcare • Biotechnology • USA • NASD

Peers: LLY JNJ PFE MRK GILD AMGN BMY ABBV VRTX REGN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-409.35	Insider Own	0.60%	Shs Outstand	1.38M	Perf Week	4.85%
Market Cap	2.97M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.37M	Perf Month	1.89%
Enterprise Value	-2.95M	PEG	-	EPS next Q	-	Inst Own	3.05%	Short Float	16.12%	Perf Quarter	-55.46%
Income	-5.47M	P/S	1.21	EPS this Y	-	Inst Trans	0.19%	Short Ratio	0.23	Perf Half Y	-86.87%
Sales	2.45M	P/B	0.19	EPS next Y	-	ROA	-85.53%	Short Interest	0.22M	Perf YTD	-86.53%
Book/sh	11.50	P/C	0.50	EPS next 5Y	-	ROE	-130.35%	52W High	840.00 -99.74%	Perf Year	-99.74%
Cash/sh	4.31	P/FCF	-	EPS past 3/5Y	12.24% -	ROIC	-67.28%	52W Low	1.95 11.05%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	70.00%	Volatility	5.60% 9.48%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-1.20	EPS Y/Y TTM	-	Oper. Margin	-207.86%	ATR (14)	0.20	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.97	Sales Y/Y TTM	-	Profit Margin	-223.57%	RSI (14)	45.64	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	8.97	EPS Q/Q	96.92%	SMA20	0.02%	Beta	0.03	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-100.00%	SMA50	-6.44%	Rel Volume	0.04	Prev Close	2.14
Employees	3	LT Debt/Eq	0.00	Earnings	-	SMA200	-95.21%	Avg Volume	970.56K	Price	2.16
IPO	Nov 21, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	36,028	Change	0.93%

Jun-24-25 08:30AM	PMGC Holdings Inc. Signs Non-Binding LOI to Acquire CNC Aerospace Manufacturer Generating $4.5 Million in Annual Revenue (GlobeNewswire) +5.83%
Jun-18-25 09:52AM	PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies (GlobeNewswire)
09:20AM	Northstrive announces initiation of Phase II of AI Development Program (TipRanks)
Jun-17-25 09:04AM	Northstrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases (GlobeNewswire)
Jun-16-25 08:00AM	PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based AS9100D & ISO 9001:2015 Certified CNC Machine Shop Serving Aerospace, Defense, and Industrial Markets for over 35 years (GlobeNewswire)
08:00AM	Loading…
Jun-09-25 08:00AM	PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Electronics Manufacturing Company (GlobeNewswire) +21.66%
May-22-25 08:16AM	NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia (GlobeNewswire) -6.02%
May-14-25 04:30PM	PMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
08:00AM	PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (GlobeNewswire)
May-13-25 08:00AM	Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22 (GlobeNewswire)
Apr-29-25 12:15PM	RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health (GlobeNewswire)
08:00AM	Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health (GlobeNewswire)
Apr-28-25 08:00AM	Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial (GlobeNewswire)
Apr-24-25 08:00AM	Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment (GlobeNewswire) -23.71%
Apr-16-25 08:00AM	PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company (GlobeNewswire) -11.34%
08:00AM	Loading…
Apr-10-25 08:00AM	Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases (GlobeNewswire) -19.55%
Mar-28-25 08:00AM	PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K (GlobeNewswire)
Mar-27-25 08:00AM	NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market (GlobeNewswire)
Mar-24-25 05:00PM	Univest Securities, LLC Announces Closing of $1.48 Million Registered Direct Offering for its Client PMGC Holdings Inc. (NASDAQ: ELAB) (GlobeNewswire)
Mar-21-25 02:41PM	PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules (GlobeNewswire) -22.97%
08:00AM	PMGC Holdings Announces Share Repurchases from Existing Shareholders (GlobeNewswire)
Mar-10-25 08:00AM	Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 (GlobeNewswire)
Mar-06-25 09:00AM	PMGC Holdings Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance (GlobeNewswire) -41.21%
Feb-27-25 08:00AM	PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group (GlobeNewswire)
Feb-26-25 08:30AM	PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market (GlobeNewswire)
Feb-18-25 07:00AM	Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Receptor Agonists (GlobeNewswire)
Feb-04-25 08:00AM	Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1 (GlobeNewswire)
Jan-31-25 10:33AM	PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies (GlobeNewswire)
Jan-30-25 08:00AM	Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 (GlobeNewswire)
Jan-27-25 09:00AM	PMGC Holdings Inc. Announces $1.9 Million in Gross Proceeds from Warrant Inducement with Institutional Investors (GlobeNewswire) -33.87%
08:00AM	Loading…
Jan-24-25 08:00AM	Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium (GlobeNewswire) +56.57%
Jan-16-25 08:31AM	PMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture (GlobeNewswire)
Jan-15-25 09:30AM	PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries (GlobeNewswire) -6.49%
Jan-02-25 03:55PM	PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy (GlobeNewswire) +8.30%
08:00AM	Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products (GlobeNewswire)
Dec-21-24 07:40AM	Elevai Labs plans name change to PMGC Holdings, redomicile to Nevada (TipRanks)
Dec-20-24 07:30PM	Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada (GlobeNewswire) +8.94%
07:30AM	Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada (GlobeNewswire)
Dec-09-24 08:00AM	Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation (GlobeNewswire)
Dec-06-24 07:30AM	Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market (GlobeNewswire)
Dec-04-24 08:00AM	Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division (GlobeNewswire) +5.03%
Nov-22-24 06:23PM	Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance (GlobeNewswire) -20.90%
05:00PM	Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess (GlobeNewswire)
Nov-14-24 02:35PM	CORRECTION - Elevai Labs Inc. (GlobeNewswire) +6.07%
09:08AM	Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update (GlobeNewswire)
Nov-04-24 05:45PM	Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange (GlobeNewswire) -30.45% +6.47%
Oct-22-24 09:54AM	Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity (GlobeNewswire)
Oct-21-24 07:30AM	Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity (GlobeNewswire) +6.34%
Oct-04-24 05:08PM	Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock (GlobeNewswire) -18.18%
Oct-03-24 03:45PM	REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations (GlobeNewswire) +54.93%
07:30AM	Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations (GlobeNewswire)
Oct-02-24 08:30AM	Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device (GlobeNewswire)
Sep-26-24 09:42PM	Altium Capital Management LP Acquires New Stake in Elevai Labs Inc (GuruFocus.com) -15.24%
Sep-24-24 05:00PM	Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB) (GlobeNewswire)
Sep-23-24 08:45AM	Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering (GlobeNewswire) -62.00%
Sep-10-24 07:30AM	Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications (GlobeNewswire)
Sep-03-24 07:30AM	Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology (GlobeNewswire) +20.12%
Aug-28-24 07:30AM	Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBio? Y100 Mitochondrial Innovation and Elevai Exosomes (GlobeNewswire) -12.28%
Aug-26-24 07:30AM	Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity Topical Exosome Serum (GlobeNewswire)
Aug-19-24 09:00AM	Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications (GlobeNewswire)
Aug-14-24 09:05AM	Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.60%
Jul-30-24 09:00AM	Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD (GlobeNewswire)
Jun-28-24 09:00AM	Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line (GlobeNewswire)
Jun-26-24 09:00AM	Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024 (GlobeNewswire)
Jun-14-24 09:00AM	Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs (GlobeNewswire) -5.10%
May-29-24 09:00AM	Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm (GlobeNewswire)
May-22-24 04:15PM	Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference (GlobeNewswire)
May-15-24 10:53PM	ELAB Stock Earnings: Elevai Labs Reported Results for Q1 2024 (InvestorPlace)
04:30PM	Elevai Labs Inc. Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 08:30AM	Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset EL-22 for The Treatment of Obesity (GlobeNewswire) +8.13%
May-01-24 04:00PM	Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare (GlobeNewswire) -6.95%
09:00AM	Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments (GlobeNewswire)
Apr-29-24 09:45AM	Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments (GlobeNewswire) +7.62%
Apr-22-24 12:08PM	Elevai Labs Signs Exclusive Distribution Deal for Taiwan (MT Newswires)
08:00AM	ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months (GlobeNewswire)
Apr-02-24 08:52AM	ELAB Stock Earnings: Elevai Labs Reported Results for Q4 2023 (InvestorPlace)
Mar-29-24 12:00PM	Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results (GlobeNewswire)
Mar-28-24 01:38PM	15 Best Beauty Stocks To Invest In (Insider Monkey)
Mar-18-24 08:30AM	Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market (GlobeNewswire) +9.03%
Feb-01-24 08:00AM	Why Is Elevai Labs (ELAB) Stock Up 57% Today? (InvestorPlace) +21.56%
Jan-24-24 08:30AM	ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office (GlobeNewswire) -10.00%
Jan-17-24 08:30AM	ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach (GlobeNewswire) -21.58%
Jan-16-24 01:48PM	Why Is Elevai Labs (ELAB) Stock Up Today? (InvestorPlace) -18.71%
08:30AM	ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology (GlobeNewswire)
Jan-02-24 09:15AM	ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences (GlobeNewswire)
Dec-12-23 05:51AM	ELAB Stock Earnings: Elevai Labs Reported Results for Q3 2024 (InvestorPlace) -6.49%
Dec-11-23 09:15AM	Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023 (GlobeNewswire) -10.19%
Dec-07-23 09:41AM	ELEVAI Labs, Inc. Expands International Distribution into Europe (GlobeNewswire) -9.75%
Nov-29-23 09:00AM	Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products (GlobeNewswire) -12.25%
Nov-24-23 12:00PM	Univest Securities, LLC Announces Closing of $6 Million Initial Public Offering of Common Stock for its Client ELEVAI Labs Inc. (Nasdaq: ELAB) (GlobeNewswire) +6.63%
11:15AM	ELEVAI Labs, Inc. Announces Closing of $6,000,000 Initial Public Offering (PR Newswire)

PMGC Holdings, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. It is involved in the production and commercialization of topical skincare products that contain its proprietary stem cell-derived Elevai Exosomes. The company was founded by Hatem Abou-Sayed, Braeden William Lichti, and Jordan R. Plews on June 9, 2020 and is headquartered in Newport Beach, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELAB

PMGC Holdings Inc

Upgrade your FINVIZ experience